gliomasPCV Only in 1p/19q Codeleted Anaplastic Gliomas
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
Patients with 1p/19q-codeleted anaplastic gliomas treated with RT + PCV are at risk of
neurocognitive deterioration. Treating these patients with PCV alone (could reduce the risk
of neurocognitive deterioration without impairing overall survival.
Phase:
Phase 3
Details
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborators:
Association de Neuro-Oncologues d'Expression Francaise Association de Neuro-Oncologues d’Expression Francaise